Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Antibiotic exposure in early life and childhood overweight and obesity: A systematic review and meta-analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Comparative studies of Insulin versus GLP-1 RA's in patients initiating injectable therapy

    Research output: Contribution to journalEditorialResearch

  1. Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Changes in Serum Sphingomyelin After Roux-en-Y Gastric Bypass Surgery Are Related to Diabetes Status

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Non-insulin pharmacological therapies for treating type 1 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The hormone glucagon-like peptide-1 (GLP-1) is released from the gut in response to food intake. It acts as a satiety signal, leading to reduced food intake, and also as a regulator of gastric emptying. Furthermore, GLP-1 functions as an incretin hormone, stimulating insulin release and inhibiting glucagon secretion from the pancreas in response to food ingestion. Evidence suggests that the action or effect of GLP-1 may be impaired in obese subjects, even in those with normal glucose tolerance. GLP-1 impairment may help explain the increased gastric emptying and decreased satiety signalling seen in obesity. Incretin impairment, probably associated with reduced insulinotropic potency of GLP-1, is also characteristic of type 2 diabetes (T2D). Therefore, it is possible that incretin impairment may contribute to the pathophysiological bridge between obesity and T2D. This review summarises current knowledge about the pathophysiology and consequences of GLP-1 and incretin impairment in obesity, and examines the evidence for an incretin-related link between obesity and T2D. It also considers the current literature surrounding the novel use of GLP-1 receptor agonists as a treatment for obesity in patients with normoglycaemia, prediabetes and T2D.
Original languageEnglish
JournalDiabetes, Obesity and Metabolism Online
Volume16
Issue number1
Pages (from-to)9-21
Number of pages13
ISSN1463-1326
DOIs
StatePublished - Jan 2014

ID: 42205461